Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Current Assets (2016 - 2025)

United Therapeutics (UTHR) has disclosed Current Assets for 17 consecutive years, with $3.7 billion as the latest value for Q4 2025.

  • Quarterly Current Assets fell 4.42% to $3.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Dec 2025, down 4.42% year-over-year, with the annual reading at $3.7 billion for FY2025, 4.42% down from the prior year.
  • Current Assets hit $3.7 billion in Q4 2025 for United Therapeutics, up from $3.5 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $4.0 billion in Q3 2024 to a low of $2.0 billion in Q1 2021.
  • Historically, Current Assets has averaged $3.2 billion across 5 years, with a median of $3.3 billion in 2022.
  • Biggest five-year swings in Current Assets: soared 45.48% in 2022 and later fell 12.66% in 2025.
  • Year by year, Current Assets stood at $2.3 billion in 2021, then skyrocketed by 45.48% to $3.4 billion in 2022, then increased by 5.05% to $3.6 billion in 2023, then rose by 9.09% to $3.9 billion in 2024, then dropped by 4.42% to $3.7 billion in 2025.
  • Business Quant data shows Current Assets for UTHR at $3.7 billion in Q4 2025, $3.5 billion in Q3 2025, and $3.8 billion in Q2 2025.